Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson's Disease Therapy

被引:219
|
作者
Woo, Seo Yeon [1 ]
Kim, Ji Hyun [3 ]
Moon, Mi Kyeong [3 ]
Han, Se-Hee [3 ]
Yeon, Seul Ki [1 ]
Choi, Ji Won [1 ]
Jang, Bo Ko [1 ]
Song, Hyo Jung [1 ]
Kang, Yong Gu [1 ]
Kim, Jin Woo [1 ]
Lee, Jaeick [2 ]
Kim, Dong Jin [1 ]
Hwang, Onyou [3 ]
Park, Ki Duk [1 ]
机构
[1] Brain Sci Inst, Ctr Neuromed, Seoul 136791, South Korea
[2] Korea Inst Sci & Technol, Doping Control Ctr, Seoul 136791, South Korea
[3] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea
基金
新加坡国家研究基金会;
关键词
MPTP MOUSE MODEL; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; CHALCONE DERIVATIVES; SYNTHETIC CHALCONE; HEME OXYGENASE-1; POTENT INDUCER; NRF2; TETRAHYDROBIOPTERIN; CELLS;
D O I
10.1021/jm401788m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although the etiology of Parkinson's disease (PD) remains elusive, recent studies suggest that oxidative stress contributes to the cascade leading to dopaminergic (DAergic) neurodegeneration. The Nrf2, signaling is the main pathway responsible for cellular defense system against oxidative stress. Nrf2 is a transcription factor that regulates environmental stress response by inducing expression of antioxidant enzyme genes. We have synthesized novel vinyl sulfone derivatives. They exhibited a broad range of activities in inducing HO-1, whose gene expression is under the control of Nrf2. Among them, compound 12g was confirmed to activate Nrf2 and induce expression of the Nrf2-dependent antioxidant enzymes NQO1, GCLC, GLCM, and HO-1, at both mRNA and protein levels in DAergic neuronal cells. This was accompanied by protection of DAergic neurons in both in vitro and MPTP-induced in vivo models of PD. In addition, compound 12g effectively resulted in attenuation of the PD-associated behavioral deficits in the mouse model.
引用
收藏
页码:1473 / 1487
页数:15
相关论文
共 50 条
  • [1] Novel neuroprotective agents for the treatment of Parkinson's disease
    George, J.
    Wilkins, S.
    Critch, N.
    Gunawan, L.
    Cortes, M.
    Liu, X.
    Laughton, K.
    Nurjono, M.
    Volitakis, I.
    Huggins, P.
    Parsons, J.
    McNaughton, M.
    Adlard, P.
    Masters, C.
    Cappai, R.
    Barnham, K.
    Gautier, E.
    Bush, A.
    Cherny, R.
    Finkelstein, D. I.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S41 - S42
  • [2] Novel Anti-Inflammatory and Neuroprotective Agents for Parkinson's Disease
    Lu, Li
    Li, Fengqiao
    Wang, Xiaomin
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (02) : 232 - 240
  • [3] Toward neuroprotective treatments of Parkinson's disease
    Kim, Kwang-Soo
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (15) : 3795 - 3797
  • [4] Neuroprotective therapy for Parkinson's disease
    Koller, WC
    EXPERIMENTAL NEUROLOGY, 1997, 144 (01) : 24 - 28
  • [5] Discovery and optimization of selective mGluR3 PAMs towards novel neuroprotective agents for the treatment of Parkinson's disease
    Manteau, Baptiste
    Schann, Stephan
    Mayer, Stanislas
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [6] Neuroprotective and neurorestorative therapy in Parkinson's disease
    JimenezJimenez, FJ
    Molina, JA
    REVISTA DE NEUROLOGIA, 1997, 25 : S185 - S193
  • [7] Concerning neuroprotective therapy for Parkinson's disease
    Uitti, R. J.
    Wszolek, Z. K.
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2006, (70): : 433 - 437
  • [8] Plant-derived neuroprotective agents in Parkinson's disease
    Fu, Wenyu
    Zhuang, Wenxin
    Zhou, Shuanhu
    Wang, Xin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2015, 7 (07): : 1189 - 1202
  • [9] Neuroprotective agents in Parkinson's disease:: clinical evidence and caveats
    Hälbig, TD
    Tse, W
    Olanow, CW
    NEUROLOGIC CLINICS, 2004, 22 (03) : S1 - S17
  • [10] Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
    Stocchi, Fabrizio
    Olanow, C. Warren
    MOVEMENT DISORDERS, 2013, 28 (01) : 3 - 7